Literature DB >> 2312196

The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.

G Nigro1, L I Comi, L Politano, R J Bain.   

Abstract

To assess the incidence, nature and evolution of cardiac disease in Duchenne muscular dystrophy, 328 patients were studied between 1976 and 1987 for periods varying from 3 to 11 years. Patients underwent regular clinical examination, electrocardiography, echocardiography and radiological assessment. Pre-clinical cardiac involvement was found in 25% of patients under 6 years old increasing to 59% between the ages of 6 and 10 years and then declining in incidence with age. Clinically apparent cardiomyopathy is first evident after 10 years of age and increases in incidence with age, being present in all patients over 18 years of age. Its clinical impact is discussed.

Entities:  

Mesh:

Year:  1990        PMID: 2312196     DOI: 10.1016/0167-5273(90)90082-g

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  186 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

3.  Unusual respiratory manifestations in two young adults with Duchenne muscular dystrophy.

Authors:  Julie Lemay; Frédéric Sériès; Mario Sénéchal; Bruno Maranda; François Maltais
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

4.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

5.  Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

Authors:  Jana Strakova; Jon D Dean; Katharine M Sharpe; Tatyana A Meyers; Guy L Odom; DeWayne Townsend
Journal:  J Mol Cell Cardiol       Date:  2014-08-24       Impact factor: 5.000

6.  Cardiac tissue velocities and strain rate in the early detection of myocardial dysfunction of asymptomatic boys with Duchenne's muscular dystrophy: relationship to clinical outcome.

Authors:  N Giatrakos; M Kinali; D Stephens; D Dawson; F Muntoni; P Nihoyannopoulos
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

7.  Beyond ambulation: Measuring physical activity in youth with Duchenne muscular dystrophy.

Authors:  Mary Killian; Maciej S Buchowski; Thomas Donnelly; W Bryan Burnette; Larry W Markham; James C Slaughter; Meng Xu; Kimberly Crum; Bruce M Damon; Jonathan H Soslow
Journal:  Neuromuscul Disord       Date:  2020-02-20       Impact factor: 4.296

8.  Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.

Authors:  Brian Bostick; Yongping Yue; Yi Lai; Chun Long; Dejia Li; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

9.  Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.

Authors:  Nalinda B Wasala; Brian Bostick; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

Review 10.  Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy.

Authors:  N Cohen; F Muntoni
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.